Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button
arrow_left sharing button
arrow_right sharing button

Protein Sciences

Uniting Drug Development Expertise with Antibody & Protein Production Services

Antibody Production Services

At Protein Sciences, we pride ourselves on being a comprehensive solution provider that unites our biologics development expertise with cutting-edge antibody production services. Our team brings a wealth of experience, that empowers us to offer a diverse range of high-quality antibody production services and avoid pitfalls in the antibody drug development process.


Key Features of our Antibody Production Services:

  • High Titer Expression: Harnessing the latest advancements in biotechnology, we excel in achieving high titer expression of antibodies, maximizing the yield for your antibodies.
  • Premium Quality: Our team of experts are comprised of skilled scientists who are well-versed in both expression and purification of antibodies. With our rigorous quality control measures throughout the antibody production process, we ensure consistent and reliable results.
  • Speedy Turnaround: Time is of the essence in research. With our high titer expression platform and optimized operation processes, we can deliver your antibodies in just 3 weeks.
  • Cost-effective Solutions: Empowered by our high titer expression platform, we achieve the same amount of antibodies with a much smaller culture volume and a shorter production time, which translates to the low cost to our customers.




Extensive Experience in the Production of Diverse Antibodies

From traditional monoclonal antibodies to innovative bispecific antibodies and various antibody fragments such as Fab fragments, VHH, and scFv, we synergize our drug-making knowledge with antibody production to deliver unparalleled results, ensuring that our clients receive top-tiered antibodies to drive groundbreaking research and therapeutic advancements.

Our Featured Antibody Production Services

Frequently Asked Questions for Antibody Production

Q: Which cell lines are used by WuXi Biologics for antibody production?

A: We primarily use CHO cells for antibody production. We have made significant investments in optimizing our cell engineering and cell growth processes to achieve high titer expression of antibodies in the CHO cells, enhancing the antibody production efficiency.

Q: How long does it typically take to produce antibodies with WuXi Biologics?

A: The antibody production timeline varies depending on several factors, including the type of antibody, the scale of production, and specific client requirements. Using our HTP platforms and high titer expression CHO cells, the timeline could be as fast as 2 weeks, with a daily throughput of 1000+ molecules.

Q: What makes WuXi Biologics’ antibody production unique?

A: Our unique advantage lies in providing valuable insights and guidance to customers throughout the entire antibody drug development process, enabling them to navigate around common pitfalls and overcome challenges effectively. This comprehensive end-to-end viewpoint and approach ensures a seamless and speedy journey from concept to market, making us a trusted and reliable partner for customers in need of antibody production services.

Q: How do I choose the right expression system (CHO, HEK293 or NS0) for my project?

A: For projects involving new molecules, CHO cells are your ideal choice because of our well-established ultra-high-titer CHO expression platform. For projects encountering issues like truncation issues, HEK293 cells are recommended. In cases where your molecules have severe aggregation issues caused by disulfide bonds in CHO or HEK293, NS0 cells can be considered as a last option.

Q: What makes a good host for producing therapeutic antibodies?

A: An optimal host expresses target antibodies with high titers, optimal glycosylation modifications, low levels of N-linked mannose-5 glycan and afucosylation, and minimal truncations. Additionally, the host should demonstrate efficient transfection, low lactate level, and rapid doubling time.

Q: Are there risks in switching my therapeutic antibody production from HEK293 to CHO?

A: These potential risks include titer variations and different glycosylation and other PTMs, sometimes truncations. The difference may lead to inconsistent efficacy, PK, challenging CMC and late-stage developments. For molecules with therapeutic purposes, it’s highly desirable to use the same CHO host from early discovery to commercial manufacturing.

Q: Why do we need ADCC?

A: Antibody-dependent cellular cytotoxicity (ADCC) is one of the most important effector mechanisms of tumor-targeting antibodies. The need for ADCC depends on the specific therapeutic strategy and mechanism of action (MOA) of your molecule. You may leverage our CHO-Fut8 technology to enhance ADCC effects.  On the other hand, sometimes ADCC effects must be eliminated, such as T-cell engagers. Antibodies can be engineered to reduce or increase the ADCC effect. Consult our specialists for unique requirements of your project.

Q: Should I consider afucosylation for my antibodies?

A: Afucosylation involves the reduction or removal of fucose in the Fc region of an antibody. This modification can significantly boost the antibody’s affinity for FcγRIIIa on natural killer (NK) cells, which in turn enhances ADCC. Careful MOA studies must be carried out to make the decision. You need to find a balance between efficacy and toxicity.

Your Project. Our Expertise.